The Depression and Bipolar Support
Alliance (DBSA) today announced its opposition to the Food and Drug
Administration's (FDA) recent recommendation to extend black box warnings
on antidepressants that suggest that young adults up to the age of 25 are
at an increased risk of suicide when they take the medications.
DBSA and other mental health advocacy groups have expressed concern
about the impact of extending the warnings to adults, which had previously
been limited to use of antidepressants in children.
"As an organization we have consistently called for research data on
the impact of antidepressants so that patients and their doctors can make
informed decisions," said Gloria Pope, DBSA's director of advocacy and
public policy. "But the recent recommendation to the FDA may have a
chilling effect on the legitimate use of antidepressants by young adults,
ultimately increasing the risk of suicide for people under the age of 25."
Depression affects approximately 34 million adult Americans in the
lifetime. Despite the availability of effective treatments that include
antidepressants, fewer than half of Americans with the illness seek
treatment, often because of stigma and limited access to care.
According to Pope, DBSA strongly urges the FDA to reconsider this
recommendation.
The Depression and Bipolar Support Alliance (DBSA) is the nation's
leading patient-directed organization focusing on depression and bipolar
disorder. The organization, which has more than 1,000 support groups
nationwide, fosters an understanding about the impact and management of these life-threatening illnesses by providing up-to-date, scientifically based tools and
information.
Assisted by a 65-member scientific advisory board comprised of the
leading researchers and clinicians in the field of mood disorders, DBSA
supports research to promote more timely diagnosis, develop more effective and
tolerable treatments, and discover a cure.
Depression and Bipolar Support Alliance
dbsalliance
Комментариев нет:
Отправить комментарий